T he article entitled "Reservations on the use of error grid analysis for the validation of blood glucose assays" (1) presents a technically accurate description of error grid analysis (EGA), but fails to address the basic idea behind it. EGA is a clinically oriented nonparametric approach to blood glucose (BG) data, based on three assumptions: 1) BG readings <3.9 mmol should be raised, 2) BG readings >10 mmol should be lowered, and 3) acceptably accurate estimates are within 20% of the reference BG or when both the estimates and reference BG are <3.9 mmol. While the latter was the "standard of the day" (2), the upper and lower limits of acceptable BG were confirmed by the Diabetes Control and Complications Trial (3).
The proposed "more effective" alternative is a generic parametric statistical technique described by Bland and Altman (4) We analyzed the data in Fig. 1 of Gough and Botvinick (1), using EGA and the Bland-Altman approach (4). We found that 46% of the estimates were accurate, as defined by the EGA, which is markedly less than the 95% we previously recommended for devices (6) . Approximately 4% of hypoglycemic readings were not detected (potentially clinically dangerous overestimates in upper zone D), and ~8% of hyperglycemic readings were not detected (potentially clinically dangerous underestimates in lower zone D). In addition, EGA identified a possible systematic error of the measuring device: it tended to underestimate BG, having 62% of its readings in the lower zones.
The Bland-Altman method correctly assessed the poor agreement between the estimate-reference values because of a 95% confidence interval for the deviations of the measuring device involving overestimates up to 8.6 mmol and underestimates of 6.6 mmol. However, the Bland-Altman approach has two major disadvantages: J) it does not provide objective criteria for agreement and 2) it relies on linear clinical equivalence across the entire BG range and suggests a data transformation when this equivalence is not accurate (4). We propose and validate a data transformation specific to the clinical nature of BG readings (34) .
The use of EGA was reported in different studies (1). However, this list (5,7-11) is incomplete, with there being many additional studies incorporating EGA (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) . What is important to point out is that in all of these published studies the authors reported both EGA results and standard statistical results. Neither these, nor our own studies, assume that either EGA or standard statistical approaches are totally adequate. One approach is not more appropriate than the other, but rather they are complementary.
Four specific issues are raised. We would like to address these separately.
1. It was stated that the "exact boundaries separating each region [i.e., zone] of the error grid are somewhat arbitrary There are problems with the pattern of the grid itself' (1). While it is true that whenever you "draw a line" different arguments can be made for different positioning, the misunderstanding here involves the basic EGA assumptions that we listed above. The example given of a 3.8 mmol estimate with a 0 mmol reference BG would never occur in reality. But if it would occur, the EGA results would be correct; both this estimated and reference BG would lead to the same and appropriate clinical action of elevating BG. In addition, we have discussed that EGA assumptions may need to be altered for different clinical and research purposes (32) , and since 1992, the EGA software has allowed users to set their own boundaries. We agree that research to evaluate ideal assumptions would be beneficial-for example, the 10% deviation criteria as proposed by the American Diabetes Association (33).
2. Appropriate criticism is that EGA relies on the assumption that reference readings are "true" or accurate reflections of the actual BG levels. However, all schemes and/or statistics for the evaluation of BG assay accuracy assume accurate reference BG values. [EGA] provides no such information." The first misunderstanding is that in reality BG readings are not normally distributed. Before parametric statistics can be employed, BG readings need to be normalized. We propose such a procedure (34) . Second, EGA can be said to offer clinical, as opposed to statistical, precision. When we applied "objective criteria" to the data in Fig.  1 of Gough and Botvinick (1), the regression model was highly significant (P < 0.0001), had a multiple R of 0.77, and a nonsignificant constant term (P = 0.47). This implies high accuracy and no systematic errors of the device, in contrast to both EGA and the Bland-Altman approach. The "objective criteria" for outlier used standardized residuals with threshold value of 1.96 (i.e., outlier probability of 0.05). This identified two outliers at reference-estimated BG levels of 13.4-21.1 and 17. 8-23.7 . EGA identified the former as upper C, leading to a potentially dangerous overtreatment, while the latter (upper B) was considered leading to an appropriate clinical decision to reduce BG. This "objective" approach did not identify the two occurrences of failure to detect hyperglycemia (18-9, 16-8.5 ) and the failure to detect hypoglycemia (3.5-4.7).
4. "Error grid analysis was not intended to be used directly in a clinical setting . . . . The actual clinical relevance is therefore limited." In fact, EGA was initially employed in a clinical setting, evaluating the accuracy of patient BG measurements, relative to reference laboratory readings (12) , and the accuracy of patient BG estimates relative to their meter readings (14, 16, 35) . EGA was specifically developed to identify the types and frequency of clinically significant errors (i.e., does meter/patient overestimate hypoglycemia [upper zones D and E], underestimate hyperglycemia [lower zones D and E], or misinterpret euglycemia for hyper-or hypoglycemia [C zones]). From a clinical perspective, it is absolutely critical to determine if a measurement device misinterprets hypoglycemia for euglycemia or hyperglycemia.
In conclusion, we agree that EGA should not be used alone and that those employing both EGA and parametric statis-DIABETES CARE, VOLUME 20, NUMBER 6, JUNE 1997 Editorial tical approaches should realize their inherent limitations (34, 36) and not extrapolate beyond them. However, these two approaches are neither incompatible nor mutually exclusive, but rather they are complementary. We will continue to employ both approaches, as we encourage others to do so.
